News
BDSX
1.260
-1.56%
-0.020
Weekly Report: what happened at BDSX last week (0415-0419)?
Weekly Report · 3d ago
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
NASDAQ · 04/17 11:44
Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
NASDAQ · 04/17 11:43
Weekly Report: what happened at BDSX last week (0408-0412)?
Weekly Report · 04/15 11:13
Biodesix Plans To Present New Data On Liquid Biopsy Technologies At AACR 2024 Annual Meeting
Benzinga · 04/09 21:02
Weekly Report: what happened at BDSX last week (0401-0405)?
Weekly Report · 04/08 11:18
S&P 500 Gains Over 1%; GCT Semiconductor Shares Spike Higher
U.S. Stocks traded higher toward the end of trading on Friday, with the Nasdaq Composite gaining more than 200 points. The Dow traded up 0.89% to 38,941.18 while the NASDAQ rose 1.26%. MediaCo Holding Inc. Shares shot up 190% on Friday after the company reported better-than-expected quarterly results. U.s. Employers added 303,000 nonfarm payrolls in March, easing the unemployment rate to 3.8%. Euro zone European shares closed lower today.
Benzinga · 04/05 18:20
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Byrna Technologies shares jumped 7.1% to $14.74 on Friday. The company reported better-than-expected first-quarter revenue and announced a CFO transition. MediaCo Holding Inc. Shares jumped 141.7% in today's mid-day session.
Benzinga · 04/05 17:06
Gold Surges Over 1%; Biodesix Shares Plummet
U.S. Stocks traded higher midway through trading on Friday. The Dow traded up 1.01% and the Nasdaq Composite gained more than 200 points. MediaCo Holding Inc. Shares shot up 207% on Friday as the company announced a deal in Saudi Arabia. U.S., employers added 303,000 nonfarm payrolls in March, easing the unemployment rate to 3.8%. Asian markets closed mixed and European shares were lower.
Benzinga · 04/05 16:06
Biodesix Shares Drop 11% After Pricing of Offerings
Biodesix shares were down 11% to $1.35 in recent trading. The stock hit its 52-week low of $2.21 on Feb. 5. The company priced its underwritten offering of 17.4 million common shares at $ 1.15 a share. Shares are down 24% in the past 12 months.
Dow Jones · 04/05 14:55
Dow Jumps Over 100 Points; US Economy Adds 303,000 Jobs In March
U.S. Stocks traded higher on Friday, with the Dow Jones gaining more than 100 points. The NASDAQ rose 0.35% and the S&P 500 traded up 0.30% on Friday. MediaCo Holding Inc. Shares shot up 126% and utilities shares fell 0.6% in trading. The Dow added 303,000 nonfarm payrolls in March, while the unemployment rate slowed to 3.8%.
Benzinga · 04/05 13:50
Biodesix prices its 17.4M shares offering at $1.15 apiece
Biodesix prices its 17.4M shares offering at $1.15 apiece. The company entered into a private placement of 760.9K shares of its series A non-voting convertible preferred stock for $46 per share. The gross proceeds to the company are expected to be $55M.
Seeking Alpha · 04/05 11:33
Biodesix Priced Its Underwritten Offering Of 17.4M Shares At $1.15/Share And Announced Concurrent Private Placement Of 760,857 Shares Of Its Series A Non-voting Convertible Preferred Stock At $46/Share, With Gross Proceeds Of $55M
Benzinga · 04/05 11:20
BIODESIX INC - PRICING OF ITS UNDERWRITTEN OFFERING OF 17.4 MLN SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $1.15 PER
Reuters · 04/05 11:17
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
Biodesix, Inc. Announces pricing of its underwritten offering of 17,391,832 shares of its common stock at a price of $1.15 per share. The company has entered into securities purchase agreements for a concurrent private placement of 760,857 shares. The gross proceeds from the offering are expected to be $55.0 million. The diagnostic solutions company is a leading company with a focus in lung disease.
Barchart · 04/05 06:17
Weekly Report: what happened at BDSX last week (0325-0329)?
Weekly Report · 04/01 11:15
Reasons to Add Cencora (COR) Stock in Your Portfolio Now
NASDAQ · 03/27 11:19
Weekly Report: what happened at BDSX last week (0318-0322)?
Weekly Report · 03/25 11:18
Biodesix Entered Into A New Master Collaborative Research Agreement With Memorial Sloan Kettering Cancer Center Under Which The Teams Will Collaborate On A Development Plan For Diagnostic Tests For Cancer
Benzinga · 03/25 10:08
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
Biodesix has entered into a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center. The teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer. BiodesIX will use its array of genomics, proteomics and data mining capabilities to develop oncology biomarker assays. Bio-Rad will provide its industry-leading digital PCR assay technology.
Barchart · 03/25 05:00
More
Webull provides a variety of real-time BDSX stock news. You can receive the latest news about BIODESIX INC through multiple platforms. This information may help you make smarter investment decisions.
About BDSX
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.